NCT03717194View on ClinicalTrials.gov

Effect of Ertugliflozin on Cardiac Function in Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

June 1, 2019

Primary Completion Date

December 31, 2022

Study Completion Date

April 30, 2023

Conditions
Type2 DiabetesHeart Failure
Interventions
DRUG

Ertugliflozin

Ertugliflozin as add-on to Metformin and/or DPP4 inhibitors in patients with inadequately controlled type 2 diabetes

DRUG

Placebo

Placebo as add-on to Metformin and/or DPP4 inhibitors in patients with inadequately controlled type 2 diabetes

Trial Locations (1)

13620

Seoul National University Bundang Hospita;, Seongnam-si

All Listed Sponsors
collaborator

MSD Korea Ltd.

INDUSTRY

lead

Soo Lim

OTHER

NCT03717194 - Effect of Ertugliflozin on Cardiac Function in Diabetes | Biotech Hunter | Biotech Hunter